Conferences 2014 San Francisco Accreditation


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Foundation for Care Management (FCM) and the International Association for CFS/ME (IACFS/ME).

FCM is accredited by the ACCME to provide continuing medical education for physicians.

FCM designates this educational activity for a maximum of 25.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program #0347-9999-13-005-L01-P*.

*This CE activity is knowledge based.

The Foundation for Care Management is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Learning Objectives IACFS/ME March 2014
Upon completion of this learning activity, the participant will be able to:

1. Recognize how medical investigators are researching CFS/ME for an epidemiological causation.

2. Identify how to appropriately order and interpret diagnostic immunological studies on patients presenting with the diagnosis of CFS/ME in order to facilitate such diagnosis; aid in determining prognosis and enable application of appropriate treatment for subsets of patients.

3.Recognize issues with patients and ERISA disability, particularly causation issues that may become relevant to the patient medical file.

4. Describe the importance of post-exercise impairment as a defining characteristic of CFS and learn about the paradigm of biomarkers developed to measure such impairment.

5. Recognize the use of “educational jargon” in public education in order to improve communication between physicians / healthcare professionals and schools regarding diagnosis and treatment of CFS in children.

6. Identify unique symptoms and complications with the severely ill CFS/ME and fibromyalgia patient and discuss management options available to clinicians.

7. Identify practical methods of behavioral assessment and individualized treatment strategies for patients with CFS/ME.

8. Identify the diagnostic criteria, pathophysiology and testing options for orthostatic intolerance in CFS/ME.

9. Identify the management of pediatric CFS/ME including using some of the current research and translating that into clinical treatment options for children.

10. Identify the current trend of using genomics in CFS/ME and how to manage the physician – patient relationship.

11. Describe the latest research in immunology including Allergy Related Immune Signatures, Plasma Cytokines and Controls before and after cardiopulmonary exercise, Natural Killer Cell Degranulation and Distribution and Genome-wide analysis of differential methylation associated with CFS/ME.

12. Describe the latest research in virology and CFS/ME including patients that have chronic pelvic pain, the occurrence of typical clinical symptoms and markers of human parvovirus B19, the pathogenesis of chronic enterovirus infection both in vivo and in vitro, and the findings from a cohort study and pathogen discovery in patients with CFS.

13. Identify treatment studies involving patients with CFS/ME such as treatment of orthostatic intolerance using Midodrine in patients with CFS, interventional effections of Baduanjin exercise on the fatigue state of patients, effects of isometric yoga on CFS, and a home based self-management for severe CFS/ME patients.

14. Participate in a discussion with CFS/ME clinicians on diagnosing difficult clinical cases.

15. Describe current research trends on CFS/ME case definitions and diagnostic criteria.

16. Identify current public health research studies involving CFS/ME such as a study of differential diagnoses from a community based sample, family aggregation studies, the ME/CFS biobank in the United Kingdom and the lay-scientific partnership that was developed, prevalence of health related characteristics of ME/CFS & FM and Environmental Sensitivities / Multiple Chemical Sensitivities, epidemiological studies involving the natural course of CFS/ME and what treatments alter the course of CFS.

17. Describe Provocation Studies in CFS/ME including diminished pulmonary ventilation and the effects of deconditioning and post exertional malaise, exercise testing including cardiopulmonary testing, and specific fitness profiles in CFS/ME.

18. Describe advances in pediatric ME/CFS research including studies on diagnosing and managing pediatric cases, impairment in motion, lab testing, milk protein hypersensitivity in pediatric cases, impact of adolescence in CFS/ME, sleep education and the effects of depression.

19. Describe advances in brain research and CFS/ME including alpha frequency and the relationship to CFS/ME, the neuroscience of fatigue in CFS/ME cases, and cognitive function.